Physician profile
Amanda Scott
NPI 1972185544
$2,755.16
in general payments reported to CMS, 2019-2025
32 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $598 · 2023: $320 · 2024: $900 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.25 | 2021-2025 | Jardiance, Ofev, Cyltezo |
| Abbvie INC. | $273.69 | 2024-2025 | |
| Lilly USA, LLC | $273.05 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $201.29 | 2022-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Novo Nordisk INC | $176.94 | 2022-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $170.23 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $150.74 | 2021-2025 | Repatha, Otezla, Otezla |
| Inspire Medical Systems, INC. | $136.37 | 2024 | Inspire |
| Lundbeck LLC | $84.42 | 2024-2025 | Rexulti, Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $77.58 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $70.00 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $69.32 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $62.10 | 2024 | Gemtesa |
| Corcept Therapeutics | $60.35 | 2024-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $47.94 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.91 | 2023-2024 | |
| Astellas Pharma US INC | $47.30 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.82 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $43.34 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $42.70 | 2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $37.49 | 2024 | |
| Radius Health, INC. | $32.14 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $28.29 | 2021-2022 | |
| Argenx US, INC. | $26.86 | 2022 | |
| Sk Life Science, INC. | $24.35 | 2022 | |
| Eisai INC. | $21.96 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.44 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.22 | 2023 | Camzyos |
| Antares Pharma, INC. | $18.09 | 2024 | Xyosted |
| Esperion Therapeutics, INC. | $17.05 | 2025 | Nexletol |
| Incyte Corporation | $14.04 | 2022 | |
| Neurocrine Biosciences, INC. | $13.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.